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Abstract
Introduction: Hidradenitis suppurativa is a complex, chronic, difficult to treat condition belonging to the spectrum of cutaneous
immune-mediated inflammatory diseases. Systemic treatment options for moderate-severe disease are limited to TNF-alpha
antagonists and other biologic agents, with limited clinical evidence.
Patient concerns: We report two adult patients with severe hidradenitis suppurativa presenting concomitant psoriatic arthritis
andmultiple medical comorbidities. Both were ineligible or resistant to adalimumab, the only biologic drug approved for the treatment
of hidradenitis.
Diagnosis:Both patients were diagnosed with severe Hurley III-stage disease and psoriatic arthritis, showing resistance to first-line
systemic treatments and a complex comorbidity profile.
Interventions:Patients underwent treatment with apremilast, an oral phosphodiesterase-4 inhibitor, approved for the treatment of
psoriatic arthritis.
Outcomes: After 16 weeks of treatment, a clinically relevant improvement of inflammatory lesions, skin- and arthritis-related pain,
and patient-reported outcomes was achieved in both patients. Apremilast was well tolerated and continued up to 48 weeks of
treatment.
Conclusion:We report the “real-life” use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and
review its potential role in the management of this severe condition.
Abbreviations: DAPSA = Disease Activity in Psoriatic Arthritis [score 0–4 remission; 5–14 low; 15–28moderate;>28 high], DLQI
= dermatology-life quality index [score 0–30], HS = hidradenitis suppurativa, HS-PGA = hidradenitis suppurativa-physician global
assessment [score 0–5], Hurley-stage = [I =mild/solitary or multiple, isolated abscess formation without scarring or sinus tracts; II =
moderate/recurrent abscesses, single or multiple widely separated lesions, with sinus tract formation; III = severe/diffuse or broad
involvement, with multiple interconnected sinus tracts and abscesses]; NRS = numerical rating score – pain score [score 0–10], PsA
= psoriatic arthritis.
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Hidradenitis suppurativa (HS) is a complex, chronic inflamma-
tory disorder of the follicular epithelium, presenting with
recurrent, suppurative lesions at inverse body sites, such as
axillary, inguinal, and anogenital regions. Like other immune-
mediated inflammatory disorders (IMIDs), HS determines a
profound impact on patient’s quality of life and shares a
significant association with cardiovascular and metabolic
comorbidities. The treatment of HS is challenging and, currently,
immune-modulating treatment is limited to adalimumab, the
only officially approved drug for the treatment of moderate-
severe disease.[1] The lack of other approved immune-modulato-
ry agents is especially frustrating in the case of patients with
multiple comorbidities, resistance, or contraindications to TNF-
alpha antagonists.
Recently, apremilast, a new class of oral-small molecules
inhibiting phosphodiesterase-4, has been introduced in the
treatment of IMIDs, such as plaque psoriasis and psoriatic
arthritis (PsA).[2] Preliminary clinical studies have also explored
Garcovich et al. Medicine (2020) 99:5 Medicinethe use of apremilast in the treatment of moderate-severe,
nonsyndromic HS, albeit with a low-comorbidity burden.
We report two patients with severe HS associated with PsA and
a complex comorbidity profile, successfully treated with




A 73-year-old man was presented with the diagnosis of HS since
the age of 52 years, previously treated with oral antibiotics. At
our observation, physical examination showed multiple fistulas
and nodules on gluteal and anal region (Hurley III stage disease),
associated with severe inflammation and pain. Clinical and
patient-reported outcome measures included: the hidradenitis
suppurativa-physician global assessment (HS-PGA=4/severe),
the numerical rating scale for pain (NRS-pain 7/10), the
dermatology-life quality index (DLQI=23), and C-reactive
protein (CRP 4.8mg/dl) (Fig. 1A and B). Ultrasound examination
confirmed the presence of complex fistulas (Fig. 1B). In addition,
concomitant PsA (DAPSA=55), with a peripheral pattern of
involvement, and localized plaque psoriasis (PASI=5) were
observed. The patient had a BMI=21.72 and was a cigarette
smoker (60 pack-years). He also had numerous comorbidities
including NHYA class-III congestive heart disease, type-2
diabetes, iron deficiency anemia related to chronic bleeding
from fistulas, and chronic renal insufficiency. Previous treatments
included systemic antibiotics (tetracyclines, rifampicin, and
clindamycin) for HS, and systemic steroids and NSAIDs for
PsA. Based on the clinical profile and contraindication to TNF-
alpha antagonists (congestive heart disease), treatment with
apremilast (30mg twice daily) was chosen. After 16 weeks of
treatment, clinical and ultrasound examinations showed
reduced inflammation and HS disease activity (HS-PGA=2/mild
disease) (Fig. 1C and D). Furthermore, a clinically relevant
improvement of PsA (DAPSA=12.8), inflammatory markers
(CRP 2.8mg/dl), and QoL (DLQI=6) was achieved. The patient
continued treatment with apremilast up to 40 weeks, also duringFigure 1. Case 1: (A) Severe Hurley III-hidradenitis suppurativa (HS-PGA 4/5)
characterized by complex sinus-tracts and abscesses. (B) Doppler ultrasound
examination showing inflamed tunnels on the right buttock, at baseline. (C)
Clinical improvement after 16 weeks of apremilast treatment. (D) Decreased
inflammation/color-flow signal after 16 weeks of treatment.
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non-HS-related surgical interventions for inguinal hernia.
Extensive surgical treatment of gluteal skin lesions was not
further indicated due to the complex comorbidity profile. At the
last clinical follow-up (week 60), the patient was still on
treatment with apremilast, without reporting any adverse
event, and maintaining clinical remission of both PsA and HS
disease.
2.2. Case 2
A 51-year-old man was examined for a 7-year duration, severe
HS (Hurley III) involving the groins and axillae. Physical
examination showed multiple sinus-tracts and nodules on the
pubic, inguinal, perianal, and axillary regions (HS-PGA=5/very
severe, NRS pain score 8/10, DLQI=25) (Fig. 2A and B). The
patient was also affected by localized plaque psoriasis and
peripheral PsA (DAPSA=48.2), type-2 diabetes, hypertension,
nonalcoholic steatohepatitis, and nephrolithiasis. He smoked 30
pack-years and had BMI=24. Previous therapies with systemic
antibiotics (carbapenems, cotrimaxozole, beta-lactams), cyclo-
sporine, corticosteroids, methotrexate, retinoids, and multiple
biologic agents (infliximab, etanercept, adalimumab, secukinu-
mab) were ineffective for both PsA and HS. Extensive surgical
treatment of inguinal disease was postponed due to symptomatic
nephrolithiasis and high inflammatory load (CRP 6.2mg/dl). Due
to lack of efficacy of previous treatments (adalimumab) and
multiple comorbidities, treatment with apremilast (30mg twice
daily) was thus initiated. Apremilast determined a clinically
relevant reduction of inflammatory lesions count, effective
control of skin-related pain (NRS-pain score 0/10), and QoL-
improvement (DLQI=9) after 16 weeks of treatment (Fig. 2C
and D). The course of HS clinical activity was consistent with
disease stabilization (HS-PGA=3/moderate), while PsA showed
a marked reduction of disease activity (DAPSA=16.7, CRP 2.7
mg/dl). Treatment with apremilast was further continued up to
48 weeks, with good tolerability, also during non-HS-related
surgical interventions (nephrolithiasis). At the last clinical follow-
up (week 72), the patient was still on active treatment with
apremilast, with a stable disease course. The option of extensiveFigure 2. Case 2: (A) Very-severe Hurley III hidradenitis suppurativa (HS-PGA
5/5) with extensive involvement of the inguinal, perineal, perianal, and inner
thigh areas. (B) Doppler ultrasound examination of left inguinal sinus-tract, at
baseline. (C) Clinical improvement after 16 weeks of apremilast treatment. (D)
Reduction of inflammation/color-flow signal, after 16 weeks of apremilast
treatment.
Table 1
Summary of clinical studies of apremilast for the treatment of nonsyndromic hidradenitis suppurativa.
Study Study design HS patients
Sex (male/female)
Mean age Intervention (duration) Clinical outcome




Apremilast 30mg b.i.d. (16 weeks) 53.3% HiScr50 responders




Apremilast 30mg b.i.d. (24 weeks) 60% HiScr50 responders




Apremilast 30mg b.i.d. (36 weeks) Significant improvement of
Sartorius score and pain
in 5 patients
Hidradenitis suppurativa clinical response (HiScr50)=50% reduction in total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining sinus count relative to baseline.
RCT= randomized clinical trial.
Garcovich et al. Medicine (2020) 99:5 www.md-journal.comsurgical intervention was discussed with the multidisciplinary
surgical team but later refused by the patient due to concern of
surgery-associated morbidity.
3. Discussion
In both patients presented herein, the numerous comorbidities
and concomitant IMID (psoriatic arthritis) posed a significant
challenge for the medical management of moderate-severe HS.
Other than adalimumab, the only FDA-approved biological
drug, the clinical evidence to support the use of immune-
modulating agents in HS is currently limited. In our cases,
treatment with apremilast allowed to achieve a clinically
relevant improvement of both IMIDs, HS-and PsA, and related
patient-reported outcomes (pain, quality of life) after a period of
16 weeks. HS disease activity improved progressively in both
patients, leading to disease stabilization of Hurley II-III disease
and effective pain control. In the case of PsA, improvement of
disease activity was more pronounced, as observed in clinical
studies. Our patients also had numerous comorbidities that,
however, did not impact the efficacy and safety of apremilast
during the follow-up period. The patients did not report any
adverse effect related to apremilast, nor abnormal laboratory
examinations and both could undergo non-HS related surgical
procedures, without interrupting treatment. The use of
apremilast in the treatment of HS has been recently reported
in two pilot clinical studies and in one case series, as summarized
in Table 1, with a total of 59 cases of HS receiving apremilast
(30mg twice daily) for up to 36 weeks.[3–5] Vossen et al reported
the efficacy and tolerability of treatment with apremilast for 16
weeks in a small, double-blind randomized clinical trial,
observing a significant clinical response (defined as a 50%
improvement of inflammatory lesions count) in 53.3% of
patients with moderate-severe disease.[3] In another open-label,
noncontrolled study, treatment with apremilast determined a
significant clinical response in 60% of patients with mild-to-
moderate HS after 24 weeks.[4] An additional case-series of
moderate-severe HS patients, who had responded poorly to
other treatments, were treated with apremilast for up to 36
weeks, reporting a significant clinical response in five out of nine
patients.[5] None of the patients treated in previous studies
presented other concomitant IMIDs or a relevant comorbidity
burden. The adverse event profile of apremilast in HS patients
seem to be consistent with the clinical data available in psoriasis
patients, with a majority of mild-moderate events being gastro-
intestinal symptoms and depression.[2] Surprisingly, a recent3
ex-vivo study of lesional HS skin described only a limited effect
of apremilast on the expression of key-inflammatory mediators,
such as IL-17A, IL-17F cytokines, and S100A12 protein.[6] On
the other hand, the clinical evidence supports the role of
apremilast in the management of moderate HS (Hurley stage II),
especially to reduce inflammatory lesion count and to control
disease activity in the long-term. Severe cases (Hurley stage III)
patients will probably benefit more from potent, targeted anti-
inflammatory treatment regimens in combination with extensive
surgery. Other advantages of apremilast include no require-
ments for laboratory monitoring and a convenient dosing-
scheme, which do not require dose-adjustments in patients with
high BMI, a typical condition in HS. Combination treatment
strategies with apremilast and other systemic agents should
consider the risk for drug interactions with strong cytochrome-
inducers, such as rifampicin, an antibiotic frequently used
in HS.[7]
In conclusion, we report the use of apremilast in two patients
with severe HS and PsA associated with a complex comorbidity
profile. Management of multimorbid adult and elderly HS
patients will pose a significant challenge in the near future, as
observed in the aging psoriatic patient population.[8] Considering
the good safety profile as well as the low-risk of drug interactions,
future controlled studies, with adequate sample sizes, should
further explore the role of apremilast in the clinical management
of hidradenitis suppurativa.Author contributions
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